Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon Aug 21, 2021 9:28am
266 Views
Post# 33744698

RE:RE:Nice to see Tripp buying shares

RE:RE:Nice to see Tripp buying shares I think thats exactly it - showing support while under fire.  He knows with a 56% rating and forums like CEO.ca and SH that he is unpopular so this way he throws himself in there with the rest of us - albeit at .35 it shouldn't be much of a risk. CEOs don't generally comment on sp and Tripp is not about to either, albeit he knows we are in the tank and that the market is skeptical about the acquisition and SZ's ability to afford it via dillution.

Honestly, I try to stay objective with this stock - its just hard for me to fathom how its sitting at these levels with the product it has. I think the big optical dissapointment here is the fact that 5 months after the Aristotle rollout we still don't have any big takers (insurers/large workplace/firefighter union/medical centres etc.) who would like to affiliate themselves with us. Buying HC was a necessity given the prescription requirement but that actually looks like a solid deal for SZ. There is no doubt that Tripp continues to market Aristotle and AVRT with the big players - when/whether we catch on remains to be seen.

Atkinson's disappointment/downgrade also hurt this big time and he won't be revising upward until he sees quarters with AVRT revenue - talk and speculation have no value here any longer.

I thought .40 was the bottom for this - surely the .35 range has to be it now. We do have a $1.25 target and there is reason for that - if you notice we have not reallly caught a break here in a long time with no surprise NRs - hopefully something breaks and some excitement is created around this which spurns investors to take the Fidelity approach and start buying.

GLTA!!

okletsmakemoney wrote: Is he trying to show support or ...??? Any thoughts?


<< Previous
Bullboard Posts
Next >>